药学学报, 2016, 51(2): 197-201
引用本文:
何琪杨. 肿瘤异质性与抗肿瘤靶向药物的耐药性[J]. 药学学报, 2016, 51(2): 197-201.
HE Qi-yang. Tumor heterogeneity and drug resistance of targeted antitumor agents[J]. Acta Pharmaceutica Sinica, 2016, 51(2): 197-201.

肿瘤异质性与抗肿瘤靶向药物的耐药性
何琪杨
中国医学科学院、北京协和医学院医药生物技术研究所, 北京 100050
摘要:
抗肿瘤靶向药物的广泛应用极大地提高了肿瘤的治疗效果,但部分患者在治疗后6~12个月出现的耐药性往往导致治疗失败。产生耐药性的原因主要是肿瘤的异质性。肿瘤异质性与肿瘤干细胞的发生、遗传物质不稳定、细胞间竞争和随机性相关。有多种机制参与肿瘤细胞对靶向药物的耐药性。肿瘤异质性和耐药性对肿瘤精准治疗是一种挑战,需要在研发抗肿瘤新药中予以关注。
关键词:    肿瘤异质性      抗肿瘤靶向药物      耐药性      生物标志物      精准医学     
Tumor heterogeneity and drug resistance of targeted antitumor agents
HE Qi-yang
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
The popular application of targeted antitumor agents has greatly improved the efficacies of tumor therapy. However, some patients develop drug resistance after the administration with them for six to twelve months, leading to the failure of treatment. The cause of it is mainly due to tumor heterogeneity. The genesis of tumor heterogeneity is closely associated with tumor stem cells, genetic instability, cell competition and stochastic events. There are a lot of mechanisms involved in the drug resistance to the targeted agents. Tumor heterogeneity and drug resistance are great challenges for precision oncology and are taken account for the process of research and development of new antitumor agents.
Key words:    tumor heterogeneity    antitumor-targeted agent    drug resistance    biomarker    precision medicine   
收稿日期: 2015-11-06
DOI: 10.16438/j.0513-4870.2015-1029
基金项目: 国家自然科学基金资助项目(81273553).
通讯作者: 何琪杨
Email: qiyang_he@vip.163.com
相关功能
PDF(272KB) Free
打印本文
0
作者相关文章
何琪杨  在本刊中的所有文章

参考文献:
[1] Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heteroge-neity in the clinic[J]. Nature, 2013, 501:355-364.
[2] Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. N Engl J Med, 2012, 366:883-892.
[3] Junker JP, van Oudenaarden A. Every cell is special:ge-nome-wide studies add a new dimension to single-cell biology[J]. Cell, 2014, 157:8-11.
[4] Magee JA, Piskounova E, Morrison SJ. Cancer stem cells:impact, heterogeneity, and uncertainty[J]. Cancer Cell, 2012, 21:283-296.
[5] Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells[J]. Cell, 2011, 146:633-644.
[6] Rappa G, Mercapide J, Lorico A. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity[J]. Am J Pathol, 2012, 180:2504-2515.
[7] Burrell RA, McClelland SE, Endesfelder D, et al. Replica-tion stress links structural and numerical cancer chromosomal instability[J]. Nature, 2013, 494:492-496.
[8] Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing[J]. Nature, 2014, 512:155-160.
[9] Cleary AS, Leonard TL, Gestl SA, et al. Tumour cell hetero-geneity maintained by cooperating subclones in Wnt-driven mammary cancers[J]. Nature, 2014, 508:113-117.
[10] Marusyk A, Tabassum DP, Altrock PM, et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity[J]. Nature, 2014, 514:54-58.
[11] Waclaw B, Bozic I, Pittman ME, et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity[J]. Nature, 2015, 525:261-264.
[12] Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer[J]. Nature, 2015, 521:489-494.
[13] Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J]. Nat Med, 2015, 21:560-562.
[14] Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR[J]. Nature, 2012, 483:100-103.
[15] Sun C, Wang L, Huang S, et al. Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma[J]. Nature, 2014, 508:118-122.
[16] Hugo W, Shi H, Sun L, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance[J]. Cell, 2015, 162:1271-1285.
[17] Nathanson DA, Gini B, Mottahedeh J, et al. Targeted ther-apy resistance mediated by dynamic regulation of extrachromo-somal mutant EGFR DNA[J]. Science, 2014, 343:72-76.
[18] Boelens MC, Wu TJ, Nabet BY, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways[J]. Cell, 2014, 159:499-513.
[19] Wang J, Hendrix A, Hernot S, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells[J]. Blood, 2014, 124:555-566.
[20] Kurtova AV, Xiao J, Mo Q, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance[J]. Nature, 2015, 517:209-213.
[21] Oshimori N, Oristian D, Fuchs E. TGF-β promotes hetero-geneity and drug resistance in squamous cell car-cinoma[J]. Cell, 2015, 160:963-976.
[22] Obenauf AC, Zou Y, Ji AL, et al. Therapy-induced tumour secretomes promote resistance and tumour progression[J]. Nature, 2015, 520:368-372.
[23] Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene abla-tion-resistant pancreatic cancer cells depend on mitochondrial function[J]. Nature, 2014, 514:628-632.
[24] Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors[J]. Nature, 2012, 487:505-509.
[25] Zhang C, Spevak W, Zhang Y, et al. Raf inhibitors that evade paradoxical MAPK pathway activation[J]. Nature, 2015, 526:583-586.
[26] Winter GE, Buckley DL, Paulk J, et al. Drug develpmeent. Phthalimide conjugation as a strategy for in vivo target protein degradation[J]. Science, 2015, 348:1376-1381.
[27] Bae SY, Hong JY, Lee HJ, et al. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer[J]. Oncotarget, 2015, 6:10146-10160.
[28] Cohen RL, Settleman J. From cancer genomics to preci-sion oncology-tissue's still an issue[J]. Cell, 2014, 157:1509-1514.
[29] Freidlib B, Korn EL. Biomarker enrichment strategies:matching trial design to biomarker credentials[J]. Nat Rev Clin Oncol, 2014, 11:81-90.